IHC results showed that in the tumor microenvironment of Emodin-treated mice there were fewer COX-2 positive cells (Figure 2B), fewer F4/80+ macrophages (Figure 2C), and fewer CD11b+ cells (Figure 2D), yet slightly more CD3+ T cells (Figure 2E) compared to AOM/DSS treated mice. Here, PTGS2 is linked to neoplasm.